ALK and non-small cell lung carcinoma: For example, non-small cell lung cancer (NSCLC) with ALK (anaplastic lymphoma kinase) rearrangements showed a higher frequency of sclerotic bone lesions compared to NSCLC with EGFR-activating mutations, or NSCLC lacking either of these targetable alterations [4].